[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642190":3},{"organization":4,"outcomesModule":7,"designInfo":29,"detailedDescription":11,"studyPopulation":32,"armGroups":33,"interventions":11,"overallOfficials":11,"centralContacts":38,"locations":11,"responsibleParty":44,"collaborators":11,"id":46,"slug":11,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":11,"enrollmentInfo":54,"targetDuration":57,"studyType":58,"phases":11,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":11},{"fullName":5,"class":6},"Qilu Hospital of Shandong University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Objective response rate",null,"From the date of first dose to achieving complete response or partial response, assessed up to 12 months",[14,17,20,23,26],{"measure":15,"description":11,"timeFrame":16},"Progression-free survival","From the date of first dose to the date of first documented progression or death from any cause, whichever occurs first, assessed up to 12 months",{"measure":18,"description":11,"timeFrame":19},"Disease control rate","From the date of first documented evidence of CR or PR to the date of PD or death, assessed up to 12 months.",{"measure":21,"description":11,"timeFrame":22},"Time to treatment failure","From the date of first dose to the date of first documented progression or death from any cause, whichever occurs first, assessed up to 12 months.",{"measure":24,"description":11,"timeFrame":25},"Overall survival","From the date of first dose to the date of death due to any cause, assessed up to 12 months",{"measure":27,"description":11,"timeFrame":28},"adverse event","From first dose to the later of 90 days after the last dose of QL1706",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":30,"timePerspective":31,"maskingInfo":11},"COHORT","PROSPECTIVE","Recurrent or Metastatic Cervical Cancer",[34,36],{"label":35,"type":11,"description":11,"interventionNames":11},"QL1706-based therapy (with or without chemotherapy\u002Fbevacizumab)",{"label":37,"type":11,"description":11,"interventionNames":11},"investigator-selected chemotherapy (with or without bevacizumab)",[39],{"name":40,"role":41,"phone":42,"phoneExt":11,"email":43},"peng Li","CONTACT","+86 18560082010","peng_li2002@163.com",{"type":45,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100642190",false,"NCT07652983","TTE Study of QL1706 in Recurrent\u002FMetastatic Cervical Cancer","Real-World Effectiveness and Safety of Iparomlimab and Tuvonralimab in Recurrent or Metastatic Cervical Cancer: A Target Trial Emulation Study","Inclusion Criteria:\n\n* Participants voluntarily agree to participate in the study and provide written informed consent.\n* Age ≥18 years at the time of signing the informed consent form.\n* Histologically confirmed recurrent or metastatic cervical cancer (FIGO 2018 stage IVB), including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.\n* Disease progression or treatment failure following prior platinum-based chemotherapy.\n* At least one measurable target lesion according to RECIST version 1.1, as assessed by CT or MRI.\n* Estimated life expectancy of at least 3 months.\n* Considered suitable by the investigator for antitumor treatment with Iparomlimab and Tuvonralimab (QL1706), either as monotherapy or in combination with other therapies, and with a planned treatment regimen including QL1706.\n\nExclusion Criteria:\n\n* Histological subtypes including sarcoma, small-cell carcinoma with neuroendocrine differentiation, or other non-epithelial malignancies.\n* History of severe hypersensitivity reaction (Grade ≥3) to Iparomlimab and Tuvonralimab (QL1706) and\u002For any of its excipients.\n* Known additional malignancy that has progressed or required active treatment within the past 3 years.\n* Active autoimmune disease requiring systemic treatment within the past 2 years (e.g., disease-modifying agents, corticosteroids, or immunosuppressive therapy); history of non-infectious pneumonitis requiring steroid treatment, or current pneumonitis.\n* Active infection requiring systemic therapy.\n* Any other medical condition, laboratory abnormality, or circumstance that, in the investigator's judgment, would make the participant unsuitable for participation in this study.","FEMALE","18 Years",{"count":55,"type":56},280,"ESTIMATED","2 Years","OBSERVATIONAL","The goal of this observational study is to evaluate the effectiveness and safety of Iparomlimab and Tuvonralimab (QL1706)-based therapy in patients with recurrent or metastatic cervical cancer who have experienced disease progression after platinum-based treatment.\n\nThe main questions it aims to answer are:\n\n* Does QL1706-based therapy improve clinical outcomes compared with investigator-selected chemotherapy in patients with recurrent or metastatic cervical cancer?\n* Does the addition of bevacizumab further improve treatment effectiveness?\n* Which patient subgroups are most likely to benefit from QL1706-based therapy? Participants receiving QL1706-based therapy or investigator-selected chemotherapy as part of routine clinical practice will be followed through real-world clinical data collection. Using a target trial emulation framework, the study will compare treatment effectiveness and safety between groups. Clinical characteristics, treatment outcomes, and adverse events will be collected for analysis. In addition, artificial intelligence-based models and multi-omics analyses will be used to identify predictive biomarkers and explore potential mechanisms of treatment response and resistance.",[32],[62,63],"Recurrent or metastatic cervical cancer","Iparomlimab and Tuvonralimab","NOT_YET_RECRUITING","2026-06-11",{"date":67,"type":68},"2026-06-17","ACTUAL",{"date":70,"type":56},"2026-06-15",{"date":72,"type":56},"2029-12-31",{"name":5,"class":6}]